Departments & Divisions
Institutes & Centers
Adolfo E Diaz Duque, M.D.
Assistant Professor / Clinical
Dr. Diaz is a Faculty member in the Division of Hematology-Oncology. He completed his medical training with honors at the Pontificia Universidad Javeriana (Colombia) and his Internal Medicine residency at New York University. He completed his Fellowship in Hematology-Oncology and also received a Master of Science in Clinical Investigation and Translational Science degree, both from University of Texas Health Science Center San Antonio. His research and clinical interests focus on improving outcomes in patients with lymphomas and also on health care disparities. He currently serves as Ambassador for the American Society of Hematology.
- 2017 - Clinical Fellowship - UT Health San Antonio/Mays Cancer Center/MD Anderson
- 2017 - MS - UT Health San Antonio
- 2011 - Residency - New York University (NYU)/Woodhull Medical Center
- 2009 - Internship - New York University (NYU)/Woodhull Medical Center
- 2001 - MD - Medical School - Pontificia Universidad Javeriana
- 11/2017 - Assistant Professor/Clinical - UT Health San Antonio/Mays Cancer Center/MD AndersonSan Antonio
Diaz AE, Mesa RA. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. doi: 10.2217/fon20170494. Epub 2017 Dec 13. PMID: 29235894; 2018 Apr. (Future Oncol; vol. 14, no. 9). Diaz Duque AE,Juan Toro MD, Francisca C. Gushiken MD
Abstract Presentation. 58th ASH Annual Meeting. San Diego, Dec 2016. Abstract # 2208
. Concurrent Acute Kidney Injury with Vancomycin Use during the Engraftment Period in Patients Undergoing Autologous Stem Cell Transplant: A Single Institution Experience; 2016 Dec. Adolfo Diaz Duque MD, Monica Cabrero MD, Farhad Ravandi MD, Naveen Pemmaraju MD, Gautam Borthakur MD, Hagop M. Kantarjian MD, Jorge E. Cortes MD, Tapan M. Kadia MD, Naval G. Daver MD, Elias Jabbour MD, Guillermo Garcia Manero MD, and Koji Sasaki MD. Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single ? Institution Experience; 2014 Dec. (Blood; vol. 124, no. 21). Abou Dalle I1, Cortes JE1, Pinnamaneni P1, Lamothe B2, Diaz Duque A1, Randhawa J1, Pemmaraju N1, Jabbour E1, Ferrajoli A1, Wierda WG1, Estrov Z1, Konopleva M1, Ravandi F1, Alvarado Y1, Borthakur G1, Gandhi V1,2, Kantarjian HM1. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia; 2014 Dec. (Blood; vol. 124, no. 21).
- American Board of Internal Medicine/Hematology
- American Board of Internal Medicine